NEA heads to Cambridge, MA's biotech hub; J&J's Imbruvica will run $130K per year;

@FierceBiotech: Merck KGaA says big M&A could jump-start stilted pipeline. Story | Follow @FierceBiotech

@JohnCFierce: Best case scenario for Lemtrada: FDA OKs for a very limited group of desperate patients. | Follow @JohnCFierce

@DamianFierce: Sanofi gets mixed FDA blessing for MS drug Lemtrada. More | Follow @DamianFierce

@EmilyMFierce: Tuberculosis R&D dropped by $30.4 million in 2012 compared with 2011. Report | Follow @EmilyMFierce

> VC mainstay New Enterprise Associates has opened an office in Cambridge, MA's Kendall Square, a biotech hub that also houses Biogen Idec ($BIIB) and Novartis ($NVS). Story

> Breakout Labs, founded by billionaire Peter Thiel, is backing biotech startups Pareto Biotechnologies and CytoVale. News

> Johnson & Johnson ($JNJ) and Pharmacyclics ($PCYC) have priced their just-approved cancer drug Imbruvica (ibrutinib) at $130,000 a year. Article

Medical Device News

@FierceMedDev: Analysts: Volcano could be an M&A fit for Abbott, Medtronic. More | Follow @FierceMedDev

@MarkHFierce: Inspired by a wine cork removal device, an Argentinian mechanic developed a surgical tool to aid difficult births. Story | Follow @MarkHFierce

@MichaelGFierce: From FierceDrugDelivery: DNA-delivering patch spurs bone growth. Piece | Follow @MichaelGFierce

> Tandem banks $120M in topped-out IPO, stirring med tech market hopes. Article

> Biomet hit with metal hip lawsuit in Canada. More

Pharma News

@FiercePharma: Tuesday's top news: Breakthrough hep C meds aren't yet for sale, but critics already taking aim at prices. Story | Follow @FiercePharma

@EricPFierce: Actavis takes aim at North Carolina plant, 310 jobs, as it looks to cut costs. More | Follow @EricPFierce

@CarlyHFierce: CFR chief angles for meeting with Adcock Ingram after top investor nixes $1.3B deal. Story | Follow @CarlyHFierce

> Novartis, Novavax tout ability to quickly whip up pandemic flu vaccines. News

> Merck KGaA hikes forecast, eyes deals as cost cuts keep delivering. More

> Supreme Court nixes Teva's last-ditch bid to block Copaxone generics. Article

Vaccines News

> Agenus, Sanofi-NIH collaboration race to develop genital herpes vaccine. Story

> Novartis to sell first piece of vaccine unit in $1.7B deal. Article

> Polio outbreak sparks fears refugees will carry virus to Europe. Report

> Dendreon to lay off more staff as Provenge disappoints. Again. More

> Novavax presents positive Phase I data for H7N9 vaccine. Story

> U.K. adds schools to flu data-gathering project. Item

Pharma Manufacturing News

> Track-and-trace bill may be finished this week. Article

> Lilly to invest $700M in plant expansions. More

> Sandoz pulls some TB drugs in India. Report

> Dendreon hopes manufacturing can save the day. Story

> FDA red-flags dangerous counterfeit ED product. Article

> New manufacturing processes could produce bird flu vax ASAP. Item

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.